Zantac
In October 2019, a class-action lawsuit was filed against Sanofi for allegedly misleadingly marketing the over-the-counter heartburn medication Zantac as safe when, according to plaintiffs, the medicine contains dangerously high…
Zantac Heartburn Medication
In October 2019, a class-action lawsuit was filed against Sanofi-Aventis U.S., Sanofi US Services, Chattem, Inc., and Boehringer Ingelheim Pharmaceuticals for allegedly failing to disclose that the over-the-counter heartburn medication Zantac exposes users to unsafe levels of the carcinogen N-Nitrosodimethylamine (NDMA). (Dimesky et al v. Sanofi-Aventis U.S., LLC, Sanofi US Services Inc., Chattem, Inc., and Boehringer Ingelheim Pharmaceuticals, Inc., Case No. 19-cv-1517, D. CT.)
Class-Action Tracker
The Latest
POWER TO THE PATIENTS
HIP HOP PSA: “We need real prices and transparency in healthcare.”
T-Mobile Home Internet
Bundle bungled.
Trial Court Rules Neora Is Not a Pyramid Scheme
But the majority of brand partners will still lose money.
Angel Publishing
Investment newsletter publisher needs to clip its wings.
CATrends: Where’s the Beef?
Lawsuits challenge the amount of meat and toppings depicted in fast-food marketing images.